Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Sunday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSE NAVB opened at $0.05 on Friday. The company has a market cap of $5.00 million, a PE ratio of -0.17 […]
More Stories
Shooter Neutralized in Incident in Midtown Manhattan
By Sam Dorman The shooter in an incident in midtown Manhattan on July 28 has been neutralized, according to authorities....
Trump Says US to Set Up Unfenced Food Centers in Gaza
By Evgenia Filimianova President Donald Trump said on July 28 that the United States will establish food centers in Gaza...
Tesla to Get Chips from Samsung’s Texas Facility in $16.5 Billion Deal
By Naveen Athrappully Tesla’s next-gen chips will be manufactured at Samsung’s upcoming semiconductor facility in Texas, the automotive company’s CEO,...
Wallabies Shattered After Last-Gasp Loss to Lions
By Melissa Woods, AAP The Wallabies have suffered a heart-breaking series loss to the British and Irish Lions after letting...
Used Cars for Less Than $20,000 Are Phasing Out: Report
By Mary Prenon The days of buying a later model pre-owned vehicle for less than $20,000 may soon become history,...
Wall Street Review: S&P 500 and Nasdaq Log Longest Record Streak in a Year
By Panos Mourdoukoutas The rally in U.S. equities gained strength this week, with both the S&P 500 Index and Nasdaq...